KODIAK SCIENCES INC. Income Tax Examination, Interest Expense
KODIAK SCIENCES INC. (KOD) reported Income Tax Examination, Interest Expense of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationInterestExpense · last filed 2025-03-27
- KODIAK SCIENCES INC. income tax examination, interest expense for fiscal 2024 was $0.00.
- KODIAK SCIENCES INC. income tax examination, interest expense for fiscal 2023 was $0.00.
- KODIAK SCIENCES INC. income tax examination, interest expense for fiscal 2022 was $0.00.
- KODIAK SCIENCES INC. income tax examination, interest expense for fiscal 2021 was $0.00.
| Period end | Income Tax Examination, Interest Expense 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-28 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-28 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |